Amgen Beats Expectations with 26% Growth in Key Areas

Amgen, a biotechnology company focused on developing innovative medicines to fight complex diseases, has announced its second-quarter earnings report for 2026. The results show strong performance across the business, with six key growth drivers increasing by 26% year over year and generating nearly 70% of product sales.

According to Amgen's chairman and chief executive officer, Robert A. Bradway, 'Our results demonstrate strong performance across our business.' He also mentioned that the company is expanding the potential of its existing medicines through new indications and advancing a new wave of pipeline molecules through Phase 3, which should continue to drive growth into the next decade.

The infographic provided by Amgen highlights additional details about the company's second-quarter results. For more information, interested parties can find the earnings press release on the company's website.